Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aliron
- Development stage
- Preclinical
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Aliron is an IgM monoclonal autoantibody cloned from a patient with Idiopathic CD4 Lymphopenia (ICL). It belongs to the autoreactive VH4-34 family and recognizes membrane targets on both T and B lymphocytes. Aliron exhibits potent complement-dependent cytotoxicity (CDC) against B lymphocytes, showing a 100-fold higher CDC potency than the anti-CD20 antibody rituximab, and is capable of killing T cells at higher concentrations. It also induces CDC in various B-cell lymphoma cell lines. Aliron is being investigated by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH) for potential therapeutic applications in B-cell lymphomas and other lymphoproliferative disorders.
Beyond the preview
Go deeper on Aliron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aliron.